NattoPharma enters partnership with KD Pharma

Report this content

NattoPharma and KD Nutra have entered into a partnership agreement to promote KD-PüR® high concentrate Omega-3s and MenaQ7® PharmaPure MK-7 combination

Oslo, Norway (24 june 2020) — NattoPharma has entered into a partnership agreement with KD Nutra – a KD Pharma Group company – to create an innovative cardiovascular-support ingredient that combines KD Nutra’s KD-PüR® high concentrate omega-3s with NattoPharma’s category leading nature-identical Vitamin K2, MenaQ7® PharmaPure MK-7.

The exclusive partnership for KD-Pür® EPA and DHA ≥ 70% Concentrates and MenaQ7® K2 is available as part of the K2ardio3™ Platform, and offers a variety of custom formulations including complementary CV ingredients such as plant sterols. KD’s formulation expertise allows for proprietary blends and delivery options.

Omega-3s are widely known and accepted for their cardiovascular benefits, and KD Pharma’s high concentrate ingredients speak directly to this advantage. KD-Pür® technology gently extracts and purifies Omega-3s in a pharmaceutical GMP certified facility. This advanced technology is capable of purifying highly sensitive Omega-3s without the use of excessive heat, chemical solvents (green technology) or oxygen.

NattoPharma will provide the missing piece of the cardiovascular puzzle with MenaQ7® PharmaPure MK-7: MenaQ7® is the only vitamin K2 as MK-7 clinically proven to provide benefits for heart health, including maintaining and promoting arterial flexibility.  MenaQ7® PharmaPure K2 was developed for its Rx division Kaydence Pharma and is part of several ongoing patient studies. Further, in addition to having two US patents for cardiovascular benefits, NattoPharma’s MenaQ7® is patent pending for the combination of omega-3s and vitamin K2.

“NattoPharma has been incubating a number of new concepts based on our high standard of clinical validation confirming true health benefits,” says NattoPharma CEO Kjetil Ramsøy. “KD Nutra’s rich history of innovation and stringent quality standards fits perfectly with NattoPharma’s principles, and the time is right to deliver an unsurpassed cardiovascular combination ingredient to the market.”

“With this exclusive partnership, KD Nutra’s K2ardio3™ platform can provide unique and comprehensive lipid and blood vessel management products for an increasing health aging demand,” says Scott Woodruff, CEO of KD Nutra.



About KD Nutra

Founded in 1988, KD Pharma has focused on improving the quality and sensory aspects of the omega-3 fish oil. The company’s early work led to a patented process based on Super Critical Fluid (SCF) technology, which consists of two processes: Supercritical Fluid Extraction (SFE) and Supercritical Fluid Chromatography (SFC, both of which gently extract and purify polyunsaturated fatty acids (PUFAs) such as fish oil. Today, KD Pharma has multiple state-of-the-art purification technologies, which allow for the production of omega-3 fish oil that is unsurpassed in quality and purity, with concentrations as high as 99%. For more information, visit


About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the supplement industry world leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements, in addition to exclusive access to the research efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of the pharmaceutical domain. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit or For more information, please contact:


For more information:

Kate Quackenbush                                                          Patricia Roch Fierro

NattoPharma Director of Communications                      KD Nutra™ Global Marketing Communication Manager

E-mail:               Email:

Documents & Links